IPG Investment Advisors LLC bought a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 8,691 shares of the life sciences company's stock, valued at approximately $2,379,000.
Other hedge funds also recently modified their holdings of the company. BlackRock Inc. purchased a new stake in Illumina in the 2nd quarter valued at $3,374,423,000. WCM Investment Management LLC boosted its holdings in Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock worth $715,579,000 after acquiring an additional 1,851,848 shares during the last quarter. Primecap Management Co. CA purchased a new position in Illumina during the 2nd quarter worth $617,981,000. Janus Henderson Group PLC grew its stake in shares of Illumina by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company's stock worth $258,924,000 after acquiring an additional 29,094 shares in the last quarter. Finally, Southpoint Capital Advisors LP raised its holdings in shares of Illumina by 20.0% in the first quarter. Southpoint Capital Advisors LP now owns 2,100,000 shares of the life sciences company's stock valued at $258,846,000 after purchasing an additional 349,536 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.
Key Headlines Impacting Illumina
Here are the key news stories impacting Illumina this week:
- Positive Sentiment: Illumina was selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT study, expected to cover about 450,000 people—roughly one in 10 residents. The project extends the company’s work in Singapore into broader clinical and public-health applications, offering a significant showcase for precision medicine. Article
- Neutral Sentiment: The large population covered by the study could create strategic opportunities, but no contract value, revenue timing, or sequencing volume for Illumina was disclosed, so the near-term financial impact is uncertain. Article
- Negative Sentiment: Citigroup raised its price target for ILMN but maintained a “sell” rating, indicating it still sees potential downside. Separately, commentary on the Q3 call cited persistent weakness in research and applied markets, despite strength in clinical sequencing and NovaSeq X placements. Article Article
Analyst Upgrades and Downgrades
ILMN has been the topic of a number of recent analyst reports. Sanford C. Bernstein reissued a "market perform" rating and set a $215.00 price target on shares of Illumina in a research report on Friday, July 31st. Wall Street Zen raised shares of Illumina from a "hold" rating to a "buy" rating in a research report on Sunday, October 11th. Guggenheim increased their price objective on shares of Illumina from $226.00 to $305.00 and gave the company a "buy" rating in a research note on Thursday, October 1st. Argus lifted their target price on shares of Illumina from $180.00 to $235.00 and gave the stock a "buy" rating in a research report on Thursday, September 3rd. Finally, Piper Sandler lifted their price target on Illumina from $225.00 to $305.00 and gave the stock an "overweight" rating in a report on Monday, September 28th. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Illumina currently has an average rating of "Hold" and an average target price of $244.24.
View Our Latest Research Report on Illumina
Insider Activity at Illumina
In other Illumina news, SVP Christensen Wedel sold 1,033 shares of the firm's stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. This trade represents a 6.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 299,336 shares of the company's stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $217.96, for a total value of $65,243,274.56. Following the sale, the director owned 1,409,851 shares in the company, valued at approximately $307,291,123.96. This represents a 17.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 1,320,108 shares of company stock valued at $288,195,392. 2.90% of the stock is owned by insiders.
Illumina Trading Up 5.1%
Shares of Illumina stock opened at $238.21 on Wednesday. Illumina, Inc. has a 52-week low of $112.65 and a 52-week high of $309.35. The stock's 50-day simple moving average is $249.74 and its 200 day simple moving average is $177.05. The stock has a market capitalization of $36.02 billion, a P/E ratio of 43.16, a P/E/G ratio of 3.08 and a beta of 1.46. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63.
Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping analysts' consensus estimates of $1.36 by $0.26. The firm had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 28.38%. The company's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the business earned $1.34 earnings per share. As a group, research analysts anticipate that Illumina, Inc. will post 5.43 EPS for the current year.
Illumina Company Profile
(
Free Report)
Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.
The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.
Featured Articles
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.